Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer?

Gulluoglu M., Karayigit E., Ozden I., Kapran Y., Dizdaroglu F.

PATHOLOGY, cilt.40, sa.1, ss.35-41, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 1
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1080/00313020701716391
  • Dergi Adı: PATHOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.35-41
  • İstanbul Üniversitesi Adresli: Evet

Özet

Aims: Histological subtyping of periampullary carcinomas is considered as a criterion for prognosis and therapeutic implications of these tumours. We assessed the immunoexpression rates of HepPar-1, CDX2 and MUC2 antibodies in different subtypes of periampullary adenocarcinomas (PAC), intestinal and pancreatobiliary, in order to assess their impact on differential diagnosis of this group of cancers. The expression of antibodies was also measured in ductal adenocarcinoma of the pancreatic head (DAPH).